Early trial data shows a drug developed using artificial intelligence can slow the growth of cancer in clinical trials. The data, presented at the American Society of Clinical Oncology conference, showed some tumors shrank by around a quarter. The compound will now be taken into more advanced trials. US biotechnology company Berg has been feeding as much data as its scientists could measure on the biochemistry of cells into a supercomputer. The aim was to let an artificial intelligence suggest a way of switching a cancerous cell back to a healthy one. It led to their first drug, named BPM31510, which tries to reverse the Warburg effect - the phenomenon in which cancerous cells change their energy supply. Data from 85 patients showed signs the approach could kill tumors. The trial was designed to test only for toxicity, but in one patient the tumor shrank by a 25%. http://www.bbc.com/news/health-36482333
